TICKERNOMICS Sign up
Last Update: 2024-12-27 15:27:57
Adagene Inc. ( ADAG ) https://www.adagene.com
1.96USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
China
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
ADAG
13.95%
SPY
32.66%
-74.51%
ADAG
SPY
108.59%
ADAG
0.00%
SPY
302.52%
ADAG
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
83.04
9.87
0.06
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-2.52
3.51
1.47
-27.30
0.00
-0.28
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-2246.02
-4.31
-2197.01
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.32
-35.94
-40.36
0.00
Other Earnings and Cash Flow Stats:
Adagene Inc. ( ADAG ) Net Income TTM ($MM) is -32.94
Adagene Inc. ( ADAG ) Operating Income TTM ($MM) is -36.82
Adagene Inc. ( ADAG ) Owners' Earnings Annual ($MM) is -47.69
Adagene Inc. ( ADAG ) Current Price to Owners' Earnings ratio is -1.55
Adagene Inc. ( ADAG ) EBITDA TTM ($MM) is -35.97
Adagene Inc. ( ADAG ) EBITDA Margin is -2197.01%
Capital Allocation:
Adagene Inc. ( ADAG ) has paid 0.00 dividends per share and bought back -0.274223 million shares in the past 12 months
Adagene Inc. ( ADAG ) has reduced its debt by 2.894738 million USD in the last 12 months
Capital Structure:
Adagene Inc. ( ADAG ) Interest-bearing Debt ($MM) as of last quarter is 22
Adagene Inc. ( ADAG ) Annual Working Capital Investments ($MM) are 0
Adagene Inc. ( ADAG ) Book Value ($MM) as of last quarter is 56
Adagene Inc. ( ADAG ) Debt/Capital as of last quarter is 31%
Other Balance Sheet Stats:
Adagene Inc. ( ADAG ) has 95 million in cash on hand as of last quarter
Adagene Inc. ( ADAG ) has 39 million of liabilities due within 12 months, and long term debt 21 as of last quarter
Adagene Inc. ( ADAG ) has 44 common shares outstanding as of last quarter
Adagene Inc. ( ADAG ) has 0 million USD of preferred stock value
Academic Scores:
Adagene Inc. ( ADAG ) Altman Z-Score is -3.45 as of last quarter
Adagene Inc. ( ADAG ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
Adagene Inc. ( ADAG ) largest shareholder is owning shares at 0.00 ($MM) value
(an insider) shares of Adagene Inc. ( ADAG ) for the amount of $ on
10.66% of Adagene Inc. ( ADAG ) is held by insiders, and 25.55% is held by institutions
Adagene Inc. ( ADAG ) went public on 2021-02-09
Other Adagene Inc. ( ADAG ) financial metrics:
FCF:-26.77
Unlevered Free Cash Flow:-40.89
EPS:-0.77
Operating Margin:-2246.02
Gross Profit Margin:-4.31
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-60.13
Beta:0.00
Buffet's Owners Earnings:-47.69
Price to Owner's Earnings:-1.55
About Adagene Inc. ( ADAG ) :
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.